Oncolytics Biotech (ONCY) Other Non-Current Liabilities (2009 - 2022)

Oncolytics Biotech (ONCY) has 11 years of Other Non-Current Liabilities data on file, last reported at $2.9 million in Q1 2022.

• On a quarterly basis, Other Non-Current Liabilities changed 0.08% year-over-year to $2.9 million in Q1 2022; TTM through Mar 2022 was $2.9 million, a 0.08% change from a year earlier, with the FY2021 full-year figure at $2.9 million, up 6.91% from the prior year.
• Other Non-Current Liabilities for Q1 2022 stood at $2.9 million, roughly flat from $2.9 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ONCY reached as high as $3.6 million in Q1 2018 and fell as low as $39720.5 in Q4 2018.
• Historically, Other Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $3.6 million in 2018.
• Across the five-year window, Other Non-Current Liabilities sank 100.0% in 2018 and surged 6798.97% in 2019, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $39720.5 in 2018, then jumped by 6798.97% to $2.7 million in 2019, then gained by 1.26% to $2.8 million in 2020, then rose by 3.44% to $2.9 million in 2021, then dropped by 0.5% to $2.9 million in 2022.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $2.9 million in Q1 2022, $2.9 million in Q4 2021, and $2.9 million in Q3 2021.